The effect of early enteral nutrition supplemented with synbiotics on lipid and glucose homeostasis in critically ill patients: A randomized controlled trial.

Autor: Seifi N; Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Nutrition, Varastegan Institute for Medical Sciences, Mashhad, Iran. Electronic address: seifin941@mums.ac.irMohammad., Amin Mohammadi M; Department of Nutrition, Varastegan Institute for Medical Sciences, Mashhad, Iran. Electronic address: MohammadiMA@varastegan.ac.ir., Dabagh AE; Department of Nutrition, Varastegan Institute for Medical Sciences, Mashhad, Iran. Electronic address: EbrahimiAl@varastegan.ac.ir., Sedaghat A; Department of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sedaghatar@mums.ac.ir., Rezvani R; Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: rezvanir@mums.ac.ir., Khadem-Rezaiyan M; Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: khademrm@mums.ac.ir., Nematy M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: khademrm@mums.ac.ir., Safarian M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: safarianm@mums.ac.ir.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2022 Jan; Vol. 16 (1), pp. 102352. Date of Electronic Publication: 2021 Nov 26.
DOI: 10.1016/j.dsx.2021.102352
Abstrakt: Background and Aims: The aim of the present study was to investigate the effects of gut microbiota modulation through synbiotic supplementation on lipid and glucose homeostasis in tube-fed critically-ill adult patients.
Methods: This study is placebo-controlled, parallel, single-center, double-blind clinical trial. 42 patients were randomly distributed in placebo and synbiotic groups to receive intervention for a maximum of 14 days. Serum levels of fasting glucose, total cholesterol, and triglycerides, insulin, and free fatty acids were obtained from blood sampling at baseline and the end of the study. Also, insulin resistance was determined by homeostasis model assessment of insulin resistance (HOMA-IR).
Result: Fasting glucose level (Day0 = 87.84 ± 15.51, Day14 = 83.76 ± 8.71 mg/dl, P = 0.51), fasting insulin level (Day0 = 9.46 ± 7.31, Day14 = 7.97 ± 5.19 mIU/L, P = 1.00), and HOMA index (Day0 = 1.89 ± 1.48, Day14 = 1.72 ± 1.17, P = 0.75) during the study were decreasing in both groups, but the decreases were not significant. Serum levels of total cholesterol, triglyceride, and free fatty acidsat the beginning of the study were 114.18 ± 43.43 mg/dl, 146.59 ± 53.99 mg/dl, 0.83 ± 0.57 mmol/L, and at the end of the study were 129.10 ± 39.05 mg/dl, 127.40 ± 91.88 mg/dl, 0.88 ± 0.77 mmol/L, respectively. None of these changes were significant either (P = 0.99, P = 0.38, P = 0.90, respectively).
Conclusions: According to our findings, synbiotics supplementation in critically ill patients has no significant effect on lipid and glucose profile.
Competing Interests: Declaration of competing interest Authors declare no conflict of interest.
(Copyright © 2021. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: